Comparison of Threshold-Based Segmentation Methods on Pre- and Post- Therapy PET Scans
|
|
|
- Eunice Hampton
- 10 years ago
- Views:
Transcription
1 M. Phillips, S.F. Barrington, D.L.G. Hill, P.K. Marsden 1 Comparison of Threshold-Based Segmentation Methods on Pre- and Post- Therapy PET Scans Michael Phillips 1 [email protected] Sally F. Barrington 1 Derek L.G. Hill 2 Paul K. Marsden 1 1 Division of Imaging Sciences, College London, London, UK. 2 IXICO Plc, Bioscience Innovation Centre, London, UK Abstract The aim of this study was to compare several threshold-based segmentation methods in delineating tumours on pre- and post- therapy PET scans both in terms of the volumes segmented and the effect on predicting survival. On a dataset of 14 patients with mesothelioma, different segmentation methods were found to correlate well with each other for pre- and post- therapy tumour volume (TV) and total lesion glycolysis (TLG) but did not correlated as well for absolute change and % change of TV and TLG between pre- and post- therapy images. This was also found for the effect of the TV and TLG on receiver operator characteristics (ROC) analysis on 6- month progression free survival (PFS) in where the segmentation method had little effect when assessing pre- or post- therapy TV and TLG but showed significant differences when using change of % change as a predictor of PFS. 1 Introduction There are a number of different threshold-based region growing segmentation methods that have been used for segmenting tumours on PET scans. These range from using a fixed standardised uptake value (SUV) threshold of 2.5, found to distinguish between malignant and benign lesions [1], to methods which take into account the background in an image, such as those defined in the PERCIST criteria [2]. Segmentation can be used to delineate PET scans to obtain tumour volume (TV) and measures combining TV and SUVs, defined as total lesion glycolysis (TLG) [3]. Pre-therapy TV/TLG and the change in TV/TLG between pre- and post- therapy scans have shown promise as useful measures for predicting patient survival in mesothelioma and other cancers [4-8]. However, there is no designated, default method of segmentation and studies have used various threshold based methods such as a fixed 2.5 SUV threshold [4,5], fixed percentage of SUV max [6], PERCIST criteria method [7], and a method using SUV mean (named GRAB) [8]. The aim of this work is to compare these and other methods to see if the segmentation method makes a significant difference to the measurement of TV and TLG and, more importantly, The copyright of this document resides with its authors. It may be distributed unchanged freely in print or electronic forms.
2 2 whether it effects the prediction of response/survival in patients. This work has been completed using 14 pre- and post- therapy PET scans from a dataset investigating the use of Sorafenib as a therapy for mesothelioma [9]. 2 Materials and Methods 2.1 PET Image Data 14 pre- and post- therapy PET scans of patients with mesothelioma were used for this GE Discovery ST or GE Discovery VCT PET scanners (Waukesha, WI). Post-therapy scans were performed ~8 weeks after the start of treatment a first line treatment of pemetrexed plus cisplatin chemotherapy, before a second line Sorafenib chemotherapy - and all patients had measurable disease, as defined by modified RECIST criteria [10]. PET image dimensions were 128 x 128 x 223, 267 or 311 (with voxel sizes of 5.47mm x 5.47mm x 3.27mm for all but one image with voxel sizes of 4.69mm x 4.69mm x 3.27mm). All PET images analysed were attenuation corrected using a smoothed CT dataset. Administered FDG dose ranged from 315 to 380MBq (median, 342MBq). The median time between administration of FDG and the start of the scan was 93min (range, min). Patients had a median age of 63 (range, 55-77) and 86% were male (12 male, 2 female). The study was approved by the UK National Research Ethics Service. 2.2 Disease Segmentation All segmentation methods used 3-D region growing using 6-voxel connectivity in a software package called PETTRA (PET Therapy Response Assessor), a software tool designed using commercial software package MATLAB 2012b (The MathWorks Inc., Natick, MA, 2000). Areas of segmentation were defined by an experienced consultant physician who decided which areas were disease and which were physiological uptake. In instances where the segmentation method clearly included areas of physiological uptake such as the liver, bladder or heart, restrictions were made using a given cubic area in which the segmentation must remain or which could remove unwanted physiological uptake, depending on which was easier. This was the same for all segmentation methods. A fixed 2.5 SUV region growing segmentation method was used as the default method of segmentation due to its simplicity and objectivity. A fixed threshold based on a percentage of SUV max was also used with various percentages, as has been done in other studies [7]. The PERCIST method, which uses a formula of the mean of the background plus two standard deviations (S.D.), was used as a threshold with the background taken as a large volume of interest (VOI) over the centre of the liver. A large VOI was used to increase the robustness of the algorithm, rather than use a smaller VOI prone to more observer variability as proposed in the PERCIST guidelines [5]. This background measure was also used for other segmentations which included a background mean and/or S.D. Two methods using the SUV mean and background uptake were included, a method by Davis et al. (2006) which uses a relative percentage threshold of the SUV max the background mean (this is then added to the SUV mean of the VOI) [11], and those defined by Nestle et al. (2005) and Nestle et al. (2007) which use a percentage of the SUV mean and a percentage of
3 the background added together [12,13]. Finally, the GRAB method, an adaptive method using the SUV mean and the background was used [14]. All the segmentation methods using the SUV mean as a starting point underwent an iterative process to continue recalculating the segmentation until the volume no longer changed or it had exceeded ten iterations with the starting SUV mean taken from a fixed 2.5 SUV threshold segmentation. Each segmentation method was used to segment disease on each of the 28 images (14 pre-therapy and 14 posttherapy). The TV and TLG was then calculated and compared for each segmentation method as was their resulting area under the curve (AUC) for receiver operating characteristics (ROC) analysis for 6-month progression free survival (PFS). 3 Results 3.1 Segmentations Each pre- and post- therapy image was found to have some disease so all 28 images had a measure for TV and TLG. Segmentation using a threshold based on the percentage of the SUV max has been omitted from the results. A variety of fixed percentages were attempted but over the entire dataset they were found to either have too low thresholds at low percentages, which segmented almost the entire body, or too high thresholds at high percentages, which clearly segmented only a fraction of the disease in the image (Figure 1, (vi)). This was also true of some of the other segmentation methods tested, particularly when using different relative thresholds. After removing segmentation methods which had problems segmenting many images, five region growing threshold segmentation methods were tested with thresholds based on: (i) a fixed 2.5 SUV [1], (ii) background uptake + 2 S.D., recommended by PERCIST [2], (iii) background mean (SUV max background mean) where 0.10 is the chosen relative threshold factor, defined by Davis et al. (2006) [11], (iv) (0.15 * SUV max ) + background mean, defined by Nestle et al., (2005) [12], and (v) a threshold based on the adaptive GRAB method [14]. The threshold used in the GRAB method is given as: Threshold = SUV mean * Threshold Factor Threshold Factor = 1 ((SUV mean MNL) / (SUV mean + MNL)) MNL = Background Mean + (Background S.D. * 3) All background means and S.D.s were taken from a 201ml volume in the middle of the liver placed by an operator. This was true of all but one dataset which had disease present at the top of the liver so a smaller volume of 119ml was used instead to make sure no disease would alter the liver mean and S.D. When using the fixed 2.5 SUV threshold over the 28 images, 21 could be segmented with no restrictions. 4 pre-therapy and 3 posttherapy images had either the segmentation area restricted from physiological uptake or the physiological uptake removed from the segmented area. Physiological uptake included the heart, liver, spleen, bladder and bowel. All other segmentation methods were perceived to visually segment the diseased areas and had reasonable restrictions put in place to stop the segmentation of physiological uptake in comparison with the fixed 2.5 SUV method. A visual comparison of the segmentation methods on datasets 1 and 7 can be seen in Figure 1. 3
4 4 Figure 1: Coronal PET slices of segmentations of two datasets (1 and 7) by the five chosen methods: (i) fixed 2.5 SUV threshold, (ii) background mean + 2 background S.D., as recommended in the PERCIST guidelines, (iii) background mean (SUV max background mean), defined by Davis et al. (2006), (iv) (0.15 * SUV max ) + background mean, defined by Nestle et al. (2005), and (v) the GRAB method. (vi) A threshold for 40% of the SUV max is also shown, as can be seen to the layman even on this 2-D coronal view, the method has clearly not segmented all of the disease. 3.2 Comparison of Segmentations As can be seen in Figure 1, all segmentations cover the same areas of disease but differences in the threshold mean the TV can often be very different. A fixed 2.5 SUV threshold had a mean TV of 586ml over the 28 scans, while segmentations using PERCIST and the Nestle method had higher mean TV of 636ml. In comparison, the Davis method and GRAB generally produced lower TVs with means of 459ml and 327ml respectively. Compared to the fixed 2.5 SUV threshold segmentation method, the other four needed less restriction from or removal of physiological uptake in segmentation, however, it is worth noting that the PERCIST and GRAB methods needed to use more user initiated VOIs to do this over the dataset. Table 1 shows the correlation between the fixed 2.5 SUV segmentation and the other four methods investigated for TV, TLG and the absolute change and absolute % change between them. The results show excellent correlation for all the segmentation methods for TV and TLG across all images but much weaker correlation when comparing the absolute change or % change between pre- and post- therapy images, with the PERCIST and GRAB methods having better correlation to using a fixed 2.5 SUV threshold than other methods.
5 Segmentation Method All Images Change % Change TV TLG TV TLG TV TLG (ii) PERCIST (iii) Davis et al. (2006) (iv) Nestle et al. (2005) (v) GRAB Table 1: Correlation between fixed 2.5 SUV threshold and other segmentation methods: shows the Pearson correlation coefficient (ppc) for TV and TLG over all 28 images and the absolute change and absolute % change over the 14 pre- and post- therapy images. For p < 0.01, pcc > over all images and for p < 0.01, pcc > for changes and % change. 3.3 Segmentation Effect on Predicting Response A comparison of ROC AUC for 6-month PFS for each segmentation method shows that all segmentation methods produce similar results when using pre- and posttherapy TV and TLG to predict 6-month PFS with all methods producing AUC between 0.8 and 0.9 (with one exception, the Davis method (iii) with a pre-therapy TV AUC of 0.938), potentially caused by just one patient being categorised differently. For pretherapy TLG all methods have identical ROC curves. However, when using change, or % change, between pre- and post- therapy TV or TLG the AUC ranges from to This suggests that while the segmentation method to obtain TV or TLG is unlikely to have a great effect when using pre- and post- therapy values to predict PFS, it is likely to have a greater impact when using the change, or % change, between pre- and post- therapy scans. TV TLG Method Pre Post Chg % C Pre Post Chg % C (i) 2.5 SUV (ii) PERCIST (iii) Davis (iv) Nestle (v) GRAB Table 2: Area under the ROC curve (AUC) for predicting progression free survival (PFS) at 6 months, using TV and TLG, for all segmentation methods. Chg = Change between pre- and post- therapy images. % C = % change between pre- and post- therapy images. 4 Conclusion This study compares five threshold-based segmentation methods to delineate disease on pre- and post- therapy PET studies. On 14 patients with mesothelioma, all the other methods were shown to correlate well with the fixed 2.5 SUV threshold method and the segmentation method had little or no effect on ROC analysis when using TV or TLG to predict 6-month PFS. However, when using the change, or % change, between pre- and post- therapy TV and TLG there was a much lower correlation between segmentation methods and a greater impact on ROC analysis where the change, or % change, between TV and TLG produced vastly different AUC depending on the segmentation method. 5
6 6 References [1] A.C. Paulino and P.A. Johnstone FDGbox? International Journal of Radiation Oncology Biology Physics, 59, 4-5. [2] R.L. Wahl, H. Jacene, Y. Kasamon and M.A. Lodge From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumours. Journal of Nuclear Medicine, 50 (1), 122S-50S. [3] S.M. Larson, Y. Erdi, T. Akhurst et al Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. Clinical Positron Imaging, 2, [4] P. Veit-Haibach, N.G. Schaefer, H.C. Steinert et al Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer, 67, [5] M.K. Song, J.S. Chung, H.J. Shin et al Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B-cell lymphoma. Cancer Science, 103, [6] T.M. Kim, J.C. Paeng, I.K. Chun et al Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B-cell lymphoma. Cancer, 119 (6), [7] H.Y. Lee, S.H. Hyun, K.S. Lee et al Volume-Based Parameter of F-18-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications. Annals of Surgical Oncology, 17, [8] R.J. Francis, M.J. Byrne, A.A. Van Der Schaaf et al Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3- dimensional volume-based analysis of serial 18F-FDG PET scans. Journal of Nuclear Medicine, 48, [9] S. Papa, S. Popat, R.Shah et al Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy. Journal of Thoracic Oncology, 8(6), [10] M.J. Byrne and A.K. Nowak Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Annals of Oncology, 15, [11] J.B. Davis, B. Reiner, M. Huser et al Assessment of 18F-PET signals for automatic target volume definition in radiotherapy treatment planning. Radiotherapy & Oncology, 80, [12] U. Nestle, S. Kremp, A. Schaefer-Schuler et al Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. Journal of Nuclear Medicine, 46, [13] U. Nestle, A. Schaefer-Schuler, S. Kremp et al Target volume definition 18F-FDG PETpositive lymph nodes in radiotherapy of patients with non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 34, [14] J.A. Boucek, R.J. Francis, C.G. Jones et al Assessment of tumour response with (18)Ffluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax a phantom study. Physics in Medicine and Biology, 53,
False positive PET in lymphoma
False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)
Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson
Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant
Uso della PET nella valutazione della risposta
La diagnostica per immagini e la radioterapia: una cooperazione nel nostro futuro Uso della PET nella valutazione della risposta Cagliari, 21 giugno 2008 Arturo Chiti Medicina Nucleare, Istituto Clinico
PET/CT: Basic Principles, Applications in Oncology
PET/CT: Basic Principles, Applications in Oncology Mabel Djang, HMS III Overview PET Basics and Limitations PET/CT - Advantages and Limitations Applications of PET/CT in oncology Summary 2 Principles of
Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
PET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
Avastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
PET/CT in Lymphoma. Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto
PET/CT in Lymphoma Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto Outline 1. Introduction: PET/CT, how does it work? 2.Current
PET. Can we afford PET-CT. Positron annihilation. PET-CT scanner. PET detection
PET-CT Can we afford PET-CT John Buscombe New technology Combines functional information-pet anatomical information-ct Machine able to perform both studies in single imaging episode PET imaging depends
Interview with David Djang, MD On PET Scan in Oncology: Principles and Practice
Interview with David Djang, MD On PET Scan in Oncology: Principles and Practice By Howard (Jack) West, MD May, 2009 Hello and welcome to the GRACE audio podcast on PET scanning. This one is with Dr. David
L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
Case Report: Whole-body Oncologic Imaging with syngo TimCT
Case Report: Whole-body Oncologic Imaging with syngo TimCT Eric Hatfield, M.D. 1 ; Agus Priatna, Ph.D. 2 ; John Kotyk, Ph.D. 1 ; Benjamin Tan, M.D. 1 ; Alto Stemmer 3 ; Stephan Kannengiesser, Ph.D. 3 ;
Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200
GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung
Advances in Lung Cancer: A Multidisciplinary Approach
Advances in Lung Cancer: A Multidisciplinary Approach Saturday, April 25, 2015 127 Public Square Cleveland, Ohio Learning Objectives About the Course This one-day course will provide a topical, clinically
HERC Coverage Guidance Advanced Imaging for Staging of Prostate Cancer Disposition of Public Comments
Table of Contents Commenters... 1 Public Comments... 2 References Provided by Commenters... 6 Commenters Identification Stakeholder A Medical Imaging & Technology Alliance (MITA), Arlington, VA [Submitted
Small Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
BEYOND 18 F-FDG: INTRODUCTION TO NEW RADIOPHARMACEUTICALS
BEYOND F-FDG: INTRODUCTION TO NEW RADIOPHARMACEUTICALS Asti Mattia Nuclear Medicine Department Santa Maria Nuova Hospital, Reggio Emilia, Italy SUMMARY: F-Labelled Choline analogues. Comparison between
PET and PET/CT in Clinical Trials
PET and PET/CT in Clinical Trials Nathan C. Hall, M.D., Ph.D. The Ohio State University Medical Center CALGB Imaging Core Lab CALGB Imaging Committee Outline Introduction to PET Positron Emitter Physics
Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method
Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method Christopher Martel, M.Sc., CHP Lisa Thornhill,, NRRPT, RT(NM) Boston University Medical Center Thyroid Carcinoma New cases and deaths in
PET POSITIVE PLEURAL PLAQUES DECADES AFTER PLEURODESIS: MESOLTHELIOMA? Ellen A. Middleton 1. Jonathan C. Daniel 2. Kenneth S.
PET POSITIVE PLEURAL PLAQUES DECADES AFTER PLEURODESIS: MESOLTHELIOMA? Ellen A. Middleton 1 Jonathan C. Daniel 2 Kenneth S. Knox 1 Kathleen Williams 1 Departments of Medicine 1 and Surgery 2, University
What If I Have a Spot on My Lung? Do I Have Cancer? Patient Education Guide
What If I Have a Spot on My Lung? Do I Have Cancer? Patient Education Guide A M E R I C A N C O L L E G E O F C H E S T P H Y S I C I A N S Lung cancer is one of the most common cancers. About 170,000
CancerStemCell Markers in Lung Cancers: Proofsof. Reservations. Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany
CancerStemCell Markers in Lung Cancers: Proofsof ConceptsandSome Reservations Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany Lung cancer: highest death rate and poorest patient survival
Malignant pleural mesothelioma P/D vs. EPP
3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy
Response Criteria for Malignant Lymphoma 2007. Cheson Criteria. Quick Reference Guide
Response Criteria for Malignant Lymphoma 2007 Cheson Criteria Quick Reference Guide Table of Contents Summary of Assessments...3 Baseline Lesion Burden...4 What isameasurable Lesion?...5 Choosing Target
LUNG CANCER SCREENING: UNDERSTANDING LUNG NODULES. 1-800-298-2436 LungCancerAlliance.org
LUNG CANCER SCREENING: UNDERSTANDING LUNG NODULES 1-800-298-2436 LungCancerAlliance.org 1 1 CONTENTS What is a Nodule?...3 Finding Nodules...4 If a Nodule Is Found...5 What Happens Next?...7 Questions
Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA
Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma
ASBESTOS MANAGEMENT REVIEW A CRITICAL REVIEW OF MEDICAL MANAGEMENT IN MALIGNANT PLEURAL MESOTHELIOMA - AUSTRALIA, 2011
ASBESTOS MANAGEMENT REVIEW A CRITICAL REVIEW OF MEDICAL MANAGEMENT IN MALIGNANT PLEURAL MESOTHELIOMA - AUSTRALIA, 2011 Dr Malcolm Feigen Senior Radiation Oncologist Radiation Oncology Centre Austin Health
QAV-PET: A Free Software for Quantitative Analysis and Visualization of PET Images
QAV-PET: A Free Software for Quantitative Analysis and Visualization of PET Images Brent Foster, Ulas Bagci, and Daniel J. Mollura 1 Getting Started 1.1 What is QAV-PET used for? Quantitative Analysis
A new predictive algorithm for aiding clinical decision-making in lung cancer
Better Care. Faster A new predictive algorithm for aiding clinical decision-making in lung cancer Y Kogan, I Sela, Y Kheiffetz, M Kleiman, Z Agur, Optimata Ltd., O Liran, N Peled, Sheba hospital, I Lazarev,
FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy
241 Ivyspring International Publisher Short Research Communication Journal of Cancer 2012; 3: 241-245. doi: 10.7150/jca.2586 FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated
Quantitative Imaging In Clinical Trials Using PET/CT: Update
Quantitative Imaging In Clinical Trials Using PET/CT: Update Paul Kinahan, Robert Doot Imaging Research Laboratory Department of Radiology University of Washington, Seattle, WA Supported by RSNA Quantitative
Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
The Science behind Proton Beam Therapy
The Science behind Proton Beam Therapy Anthony Zietman MD Shipley Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School Principles underlying Radiotherapy Radiation related
ARTICLE IN PRESS. European Journal of Radiology xxx (2009) xxx xxx. Contents lists available at ScienceDirect. European Journal of Radiology
European Journal of Radiology xxx (2009) xxx xxx Contents lists available at ScienceDirect European Journal of Radiology journal homepage: www.elsevier.com/locate/ejrad Three-dimensional evaluation of
GE Healthcare. pet/ct for simulation. Precision in motion.
GE Healthcare pet/ct for simulation. Precision in motion. Patient profile H: 5 10 W: 370 lbs BMI: 53 Each cancer patient is just as unique as his or her cancer. Approaches to cancer treatment are changing
QUANTITATIVE IMAGING IN MULTICENTER CLINICAL TRIALS: PET
Centers for Quantitative Imaging Excellence (CQIE) LEARNING MODULE QUANTITATIVE IMAGING IN MULTICENTER CLINICAL TRIALS: PET American College of Radiology Clinical Research Center v.1 Centers for Quantitative
NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER
Media Release April 7, 2009 For Immediate Release NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER London, Ontario Improved hybrid imaging techniques developed
The Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
Summary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
In Practice Whole Body MR for Visualizing Metastatic Prostate Cancer
In Practice Whole Body MR for Visualizing Metastatic Prostate Cancer Prostate cancer is the second most common cancer in men worldwide, accounting for 15% of all new cancer cases. 1 Great strides have
CPT CODE PROCEDURE DESCRIPTION. CT Scans 70450 CT HEAD/BRAIN W/O CONTRAST 70460 CT HEAD/BRAIN W/ CONTRAST 70470 CT HEAD/BRAIN W/O & W/ CONTRAST
CPT CODE PROCEDURE DESCRIPTION CT Scans 70450 CT HEAD/BRAIN W/O CONTRAST 70460 CT HEAD/BRAIN W/ CONTRAST 70470 CT HEAD/BRAIN W/O & W/ CONTRAST 70480 CT ORBIT W/O CONTRAST 70481 CT ORBIT W/ CONTRAST 70482
Malignant Mesothelioma State of the Art
Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG
THORACIC DIAGNOSTIC ASSESMENT PROGRAM (DAP) PATIENT INFORMATION FOR:
central east regional cancer program in partnership with cancer care ontario THORACIC DIAGNOSTIC ASSESMENT PROGRAM (DAP) PATIENT INFORMATION FOR: Thoracic dap booklet March2012.indd 1 SCHEDULED TESTS YOUR
Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care
Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care Saturday, April 27, 2013 Cleveland Marriott Downtown at Key Center 127 Public Square Cleveland, Ohio Learning
There must be an appropriate administrative structure for each residency program.
Specific Standards of Accreditation for Residency Programs in Radiation Oncology 2015 VERSION 3.0 INTRODUCTION The purpose of this document is to provide program directors and surveyors with an interpretation
Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7
Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7 Authors Ronald C. Walker 1,2, Tracy L. Brown 3, Laurie B. Jones-Jackson
Disclosures for Elena Zamagni
Prognostic relevance of 18F-FDG PET/CT in newly diagnosed multiple myeloma patients receiving upfront autologous stem-cell transplantation: a prospective study Zamagni E. 1, Nanni C. 2, Patriarca F. 3,
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James
This factsheet aims to outline the characteristics of some rare lung cancers, and highlight where each type of lung cancer may be different.
There are several different kinds of lung cancer, often referred to as lung cancer subtypes. Some of these occur more often than others. In this factsheet we will specifically look at the subtypes of cancers
IAEA-TECDOC-1603. The Role of PET/CT in Radiation Treatment Planning for Cancer Patient Treatment
IAEA-TECDOC-1603 The Role of PET/CT in Radiation Treatment Planning for Cancer Patient Treatment October 2008 IAEA-TECDOC-1603 The Role of PET/CT in Radiation Treatment Planning for Cancer Patient Treatment
FATAL PNEUMONITIS ASSOCIATED WITH INTENSITY-MODULATED RADIATION THERAPY FOR MESOTHELIOMA
RAPID COMMUNICATION FATAL PNEUMONITIS ASSOCIATED WITH INTENSITY-MODULATED RADIATION THERAPY FOR MESOTHELIOMA AARON M. ALLEN, M.D.,* MARIA CZERMINSKA, M.S.,* PASI A. JÄNNE, M.D., PH.D., DAVID J. SUGARBAKER,
Crosswalk for Positron Emission Tomography (PET) Imaging Codes G0230 G0030, G0032, G0034, G0036, G0038, G0040, G0042, G0044, G0046
Positron Emission Tomography (PET) CPT to HCPCS Level Crosswalk Changes below from CMS Change Request 3741 Transmittals 518 & 31 published on April 1, 2005; mplementation of CPT codes are effective January
SMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
Endpoint Selection in Phase II Oncology trials
Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill [email protected] Primary endpoints in Phase II trials Recently looked at journal articles
Malignant Mesothelioma
Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
Malignant Mesothelioma
Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA
2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate
Rb 82 Cardiac PET Scanning Protocols and Dosimetry. Deborah Tout Nuclear Medicine Department Central Manchester University Hospitals
Rb 82 Cardiac PET Scanning Protocols and Dosimetry Deborah Tout Nuclear Medicine Department Central Manchester University Hospitals Overview Rb 82 myocardial perfusion imaging protocols Acquisition Reconstruction
London Cancer. Mesothelioma Lung Protocols
London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta
A new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; [email protected] (2) Steven
Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW
The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.
Management of Non-Small Cell Lung Cancer Guide for General Practitioners
Management of n-small Cell Lung Cancer Guide for General Practitioners Clinical Stage I Cancer only in one lobe of lung and
There are 2 types of clinical trials that are of interest to the. The Clinical Trials Network of the Society of Nuclear Medicine
The Clinical Trials Network of the Society of Nuclear Medicine Michael M. Graham, PhD, MD The Clinical Trials Network of the Society of Nuclear Medicine was formed to provide quality assurance of both
RESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?
RESEARCH EDUCATE ADVOCATE Just Diagnosed with Melanoma Now What? INTRODUCTION If you are reading this, you have undergone a biopsy (either of a skin lesion or a lymph node) or have had other tests in which
Update on Clinical Trials and Foundation Funded Grants
Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation www.curemeso.org Delivering the Diagnosis Delivering the Diagnosis Day 1 Taking control
Independent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens
Independent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens Assunta De Rienzo, Ph.D. 1, Robert W. Cook, Ph.D. 2,
Probe: Could you tell me about when?
PERIODIC ASSESSMENT OF TREATMENT AND VITAL/DISEASE STATUS Periodic Assessment of Cancer Treatment and Disease Status (To be administered to patient at 3 months and reviewed at 6, 9 and 12 months) Instructions:
Recommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who
Elements of PET/CT Reporting
Elements of PET/CT Reporting 1. Clinical History a. Indication i. tumor type ii. abnormality to be evaluated iii. specific clinical question b. Relevent history i. biopsy results ii. chemotherapy iii.
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
Houston Cancer Institute
Houston Cancer Institute A personal path to healing Memorial-West Houston Katy Northwest Houston Southeast Houston Sugar Land Convenience for Patients State of the Art Therapies and Diagnosis Real Support
How to measure effect of treatment? chest radiography CT scan MRI scan PET scan ultrasound physical examination bone scintygraphy
respons meting Bonne Biesma Franz Schramel Terschelling 2012 How to measure effect of treatment chest radiography CT scan MRI scan PET scan ultrasound physical examination bone scintygraphy guidelines
Tumor regression with Ayurvedic Rasayana therapy in Squamous Cell Carcinoma of lungs. A Case Report
Rasamruta -7:15 August, 2015 Tumor regression with Ayurvedic Rasayana therapy in Squamous Cell Carcinoma of lungs A Case Report Yogesh Bendale, Vineeta Bendale, Poonam Birari-Gawande, Avinash Kadam and
NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
Releasing Nuclear Medicine Patients to the Public: Dose Calculations and Discharge Instructions
Educational Objectives Releasing Nuclear Medicine Patients to the Public: Dose Calculations and Discharge Instructions Robert E. Reiman, MD Radiation Safety Division Duke University Medical Center Durham,
Us TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
Mesothelioma. 1995-2013, The Patient Education Institute, Inc. www.x-plain.com ocft0101 Last reviewed: 03/21/2013 1
Mesothelioma Introduction Mesothelioma is a type of cancer. It starts in the tissue that lines your lungs, stomach, heart, and other organs. This tissue is called mesothelium. Most people who get this
Introduction Objective Methods Results Conclusion
Introduction Objective Methods Results Conclusion 2 Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma a rare cancer associated with long latency period (i.e. 20 to 40 years),
Medical Physics and Radioactivity
Medical Physics and Radioactivity Radioactivity Unstable nucleus Electromagnetic wave particle Atoms which emit electromagnetic radiation or a particle by the spontaneous transformation of their nucleus
Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
Lymphoma. Measurability of Quality Performance Indicators Version 2.0
Lymphoma Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Lymphoma Clinical Quality Performance Indicators (September 2013) Lymphoma Data Definitions V2.0 (September
